| 000 | 01833 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250517203348.0 | ||
| 264 | 0 | _c20190617 | |
| 008 | 201906s 0 0 eng d | ||
| 022 | _a1872-7980 | ||
| 024 | 7 |
_a10.1016/j.canlet.2018.02.036 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHu, Yunhui | |
| 245 | 0 | 0 |
_aSabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer. _h[electronic resource] |
| 260 |
_bCancer letters _c06 2018 |
||
| 300 |
_a47-59 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 |
_aDoxorubicin _xadministration & dosage |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xdrug effects |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGene Expression Regulation, Neoplastic _xdrug effects |
| 650 | 0 | 4 |
_aGossypol _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterleukin-6 _xmetabolism |
| 650 | 0 | 4 | _aMCF-7 Cells |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aNeoplastic Stem Cells _xdrug effects |
| 650 | 0 | 4 |
_aSTAT3 Transcription Factor _xmetabolism |
| 650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 700 | 1 | _aYagüe, Ernesto | |
| 700 | 1 | _aZhao, Jing | |
| 700 | 1 | _aWang, Luyao | |
| 700 | 1 | _aBai, Jingchao | |
| 700 | 1 | _aYang, Qianxi | |
| 700 | 1 | _aPan, Teng | |
| 700 | 1 | _aZhao, Hui | |
| 700 | 1 | _aLiu, Jingjing | |
| 700 | 1 | _aZhang, Jin | |
| 773 | 0 |
_tCancer letters _gvol. 423 _gp. 47-59 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.canlet.2018.02.036 _zAvailable from publisher's website |
| 999 |
_c28137385 _d28137385 |
||